cas 47173-80-8|| where to buy Boc-D-Ser(Bzl)-OH

Produktname:Boc-D-Ser(Bzl)-OH

IUPAC Name:(2R)-3-(benzyloxy)-2-{[(tert-butoxy)carbonyl]amino}propanoic acid

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM253098-100g	in stock	ɐǲ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 47173-80-8 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:47173-80-8; Molekulare Formel:C15H21NO5; Schmelzpunkt:-; SMILES-Code:O=C(O)[C@@H](COCC1=CC=CC=C1)NC(OC(C)(C)C)=O; Dichte:

: Katalognummer:CM253098; Molekulargewicht:295.34; Siedepunkt:456.2°C at 760 mmHg; Mdl-Nr.:MFCD00038248; Lagerung:Store at 2-8°C.

: Amino Acids and Peptides; Amino acids are organic compounds containing a basic amino group and an acidic carboxyl group. Because amino acids contain both amino and carboxyl groups, they can be polymerized in an end-to-end manner, removing a molecule of water to form a covalent amide bond or peptide bond. Many amino acids are linked together end to end to form a polypeptide. Amino acids and peptides are important components in the fields of medicine and life sciences.; amino acids wholesale; if you are finding amino acids wholesaler in china, we will be your best choose! We have our own factory, so we can give you a cheap price!

: Elinzanetant; On January 8, 2024, Bayer announced positive top-line results of the pivotal Phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo. Elinzanetant successfully met all four primary endpoints and all three key secondary endpoints in both studies. Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist for the non-hormonal treatment of moderate to severe VMS associated with menopause. Elinzanetant may address moderate to severe VMS by modulating a group of estrogen sensitive neurons in the hypothalamus region of the brain (the KNDy neurons) which, with the decrease of estrogen, become hypertrophic and lead to a hyperactivation of the thermoregulatory pathway, consequently disrupting body heat control mechanisms resulting in VMS. Elinzanetant may also decrease sleep disturbances associated with menopause.